Article
HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 15 Aug 2004
Demeter Lisa M, Ribaudo Heather J, Erice Alejo, Eshleman Susan H, Hammer Scott M, Hellmann Nicholas S, Fischl Margaret A
Abstract excerpt
We evaluated phenotypic and genotypic markers of drug resistance in human immunodeficiency virus type 1 (HIV-1) at the time of virologic failure (VF) in subjects in the AIDS Clinical Trials Group Protocol 388 (ACTG 388) who received lamivudine-zidovudine (or lamivudine-stavudine) and either indinavir, efavirenz-indinavir, or nelfinavir-indinavir. At VF, phenotypically susceptible HIV-1 was found in 55% of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.